RBM10 loss promotes EGFR-driven lung cancer and confers sensitivity to spliceosome inhibition. Bao Y, Zhang S, Zhang X, Pan Y, et al. Cancer Res 2023 Feb 28:CAN-22-1549. doi: 10.1158/0008-5472.CAN-22-1549.

Read + Share

Amedeo Smart

Independent Medical Education

Bao Y, Zhang S, Zhang X, Pan Y, et al. RBM10 loss promotes EGFR-driven lung cancer and confers sensitivity to spliceosome inhibition. Cancer Res 2023 Feb 28:CAN-22-1549. doi: 10.1158/0008-5472.CAN-22-1549.
PMID: 36853175